Search company, investor...



Acquired | Acquired

Total Raised


About Apitope

Apitope is a European biotech company focused on the discovery and development of revolutionary disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves' disease, FVIII intolerance and uveitis. The Company has a patented discovery platform which enables selection of disease-modifying peptide therapies for the autoimmune/allergic disease of interest; and has already generated a pipeline of seven programmes in clinical and preclinical development, of which the lead programme in multiple sclerosis is partnered with Merck Serono. The discovery engine selects Apitopes - Antigen Processing Independent epiTOPES. Apitopes are soluble, synthetic peptides from the human sequence which can selectively suppress abnormal immune responses and reinstate the normal immune balance. On August 8th, 2021, Apitope was acquired by Worg Pharmaceuticals, terms of the transaction were not disclosed.

Headquarters Location

Agoralaan Building A-bis

Diepenbeek, 3590,


Missing: Apitope's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Apitope's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Apitope

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Apitope is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

1,568 items

Apitope Patents

Apitope has filed 23 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Diseases of the eye and adnexa, Disorders of choroid and retina, Disorders of sclera and cornea, Rare diseases, G protein coupled receptors


Application Date


Grant Date



Related Topics

Diseases of the eye and adnexa, Disorders of choroid and retina, Disorders of sclera and cornea, Rare diseases, G protein coupled receptors



Latest Apitope News

Worg Pharmaceuticals to Acquire Apitope International

Sep 29, 2021

Worg Pharmaceuticals to Acquire Apitope International Search jobs Worg Pharmaceuticals to Acquire Apitope International     Hangzhou, China and Diepenbeek, Belgium, September 23, 2021: Worg Pharmaceuticals (Hangzhou) Co., Ltd (“Worg”), a clinical stage biopharmaceutical company developing new treatments for allergy, and Apitope International NV (“Apitope”), a clinical stage biotech company focused on autoimmune diseases, today announce that they have entered into an asset purchase agreement (the “Agreement”) under which Worg will acquire Apitope’s proprietary platform and therapeutic pipeline. Apitope’s innovative pipeline consists of clinical, preclinical and discovery stage assets for the treatment of a range of autoimmune diseases with significant unmet medical need. Apitope is developing potential first-in-class antigen-specific immunotherapies targeting the immunological basis of autoimmune diseases. Its novel discovery platform enables the identification and selection of highly specific epitopes which reinstate immune tolerance, known as “apitopes®”. Apitope has built a robust development pipeline of antigen-specific immunotherapies. The lead compounds include the first potential disease-modifying therapy for Graves' disease, the first innovative treatment for the disease in more than 60 years, as well as potential first-in-class antigen-specific immunotherapies for Factor VIII inhibitors and multiple sclerosis. In addition, other innovative early stage programs include projects for uveitis, myocarditis and rheumatoid arthritis. “The assets that we will acquire fit well with Worg’s business strategy by overlapping with our current business in allergy immunotherapies. With this acquisition, we will be able to expand our immunotherapy pipeline based on the same core immunology knowledge. We are pleased to take the leading role of these innovative therapies and bring new treatment options to patients”, said Andrew Xu, Chief Executive Officer of Worg. Rainer Henning, Chief Scientific Officer and Head of European Operations for Worg added: “We are very excited to add the Apitope platform to our portfolio. This transaction expands our immunotherapy pipeline from allergies into autoimmune diseases and we are fully committed to advance the products through clinical development. We see great potential to offer innovative treatments with the potential of providing a cure to patients suffering from a range of autoimmune diseases.”   Stéphane Verdood, Chairman and Hayley French, Chief Executive Officer of Apitope, commented: “We are very pleased to join forces with Worg which will drive the development of our promising pipeline of first-in-class immunotherapies to give patients novel, effective and safe treatments. We believe the combination of Apitope’s innovative programs and Worg’s drug development expertise will maximise the potential of these projects and address significant unmet medical needs.” Editor Details

Apitope Frequently Asked Questions (FAQ)

  • Where is Apitope's headquarters?

    Apitope's headquarters is located at Agoralaan, Diepenbeek.

  • What is Apitope's latest funding round?

    Apitope's latest funding round is Acquired.

  • How much did Apitope raise?

    Apitope raised a total of $36.4M.

  • Who are the investors of Apitope?

    Investors of Apitope include Worg Pharmaceuticals, LRM Capital, Wyvern Fund, Vesalius BioCapital, Arthurian Life Sciences and 9 more.

  • Who are Apitope's competitors?

    Competitors of Apitope include AmideBio, TetraGenetics, Bloomage BioTech, Variation Biotechnologies, Alba Therapeutics, Pevion Biotech, Critical Biologics, American Stem Cell, Bayhill Therapeutics, Aliva Biopharmaceuticals and 14 more.

Compare Apitope to Competitors


REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.

Replikun Biotech

Replikun Biotech is a immunotherapy company founded in March 2005. The company is focused on the development and commercialization of immunotherapies to combat infectious diseases and cancer. Replikun offers licensing and collaboration opportunities based on KUNrep Vectors, its gene delivery and expression technology. The technology is underpinned by an integrated portfolio of granted and pending patent applications which comprise the KUNrep Vectors, their pharmaceutical applications and methods of manufacture. Replikun Biotech is conducting pre-clinical studies of two products: an investigational oncology candidate and a HIV vaccine, both developed using the KUNrep Vector system.

Osprey Pharmaceuticals

Osprey Pharmaceuticals is a privately held biotechnology company focused on developing and commercializing a first-in-class family of therapeutic proteins (Leukocyte Population Modulators) capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The company's proprietary LPMs selectively and systematically destroy disease-related leukocytes by infiltrating the chemokine system that regulates the movement and activity of leukocytes.

Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Hawaii Biotech

Hawaii Biotech (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. The company has developed expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. Lead vaccine candidates in clinical development target the West Nile virus and Dengue virus. Additional recombinant protein subunits vaccine candidates produced from this protein production platform are currently under development.

Norgen Biotek Logo
Norgen Biotek

Norgen Biotek Corp. is a biotechnology company focusing principally on advancing sample preparation products for nucleic acid (DNA & RNA) and protein purification, clean-up and concentration. Norgen has one platform technology with many applications based on a resin that can be applied in the purification of DNA, RNA and proteins. The uniqueness and novelty of this technology has been recognized by the National Research Council through awarding Norgen the prestigious "Innovation Leader Award for 2003". The company holds more than a dozen issued patents and several others are pending. Norgen currently manufactures over 40 products that are used by researchers working in genomics and proteomics in academia, pharma/biotech companies, and government institutions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.